Home » Authors » Catherine Hollingsworth

Articles by Catherine Hollingsworth

Trevena Raises $35M in Series B To Fund Heart Failure Study

July 14, 2010

By Catherine Hollingsworth

iPierian Attracts New Investor Google in $22M Series B Round

July 9, 2010

By Catherine Hollingsworth

Bionovo to Raise $15M to Advance Plant-Based Pipeline

July 8, 2010

By Catherine Hollingsworth

Angion Advancing Phase II Drug for Renal Transplants

July 7, 2010

By Catherine Hollingsworth

Sunesis' $28.5M Stock Sale to Fund Voreloxin Phase III Trial

July 2, 2010

By Catherine Hollingsworth

Calistoga's $40M Series C Moves PI3K Inhibitor to Trial

July 1, 2010

By Catherine Hollingsworth

Obesity Data Show Drugs May Offer More Than Weight Loss

June 30, 2010

By Catherine Hollingsworth

Morphosys to Pay Xencor $13M Up Front for CLL Compound

June 29, 2010

By Catherine Hollingsworth

Metabolex Inks Diabetes Deal (Again); $375M from Sanofi

June 28, 2010

By Catherine Hollingsworth

Molecular Insight Stock Up on Phase II Cancer Data

June 25, 2010

By Catherine Hollingsworth

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
Deep brain stimulation from the shallows: tomorrow’s BCI technology?
BioWorld
Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
Deerfield-backed Boulevard, Metis pen $1.6B trispecific TCE deal
BioWorld
A U.S. biotechnology company founded by Deerfield Management Company L.P. licensed exclusive rights to Metis Techbio Co. Ltd.’s preclinical trispecific T-cell...